- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Drug discovery
Lilly suing J&J for patent rights in Alzheimer's drug race
April 25, 2013
Bloomberg NewsEli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay
availability of a potential treatment for Alzheimer’s disease.
MoreIU medical school's push to launch startups bears fruit
April 13, 2013
J.K. WallThe Indiana University School of Medicine has launched 12 companies in the past 18 months—a burst of startup activity
the school has never seen before.
MoreJ&J wins OK for first in new class of diabetes drugs
March 31, 2013
Bloomberg NewsJohnson & Johnson, the world’s largest seller of health-care products, won approval for the first in a new family
of diabetes drugs, giving them the edge against rivals including Eli Lilly and Co. that are developing similar medicines.
MoreLilly, Boehringer submit diabetes drug to FDA
March 25, 2013
Associated PressEli Lilly and Co. said Monday that it has submitted a new type 2 diabetes treatment it is developing with German drugmaker
Boehringer Ingelheim to the Food and Drug Administration.
MoreCourt may decide if drugmakers can pay to delay generics
March 25, 2013
Associated PressFederal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors
to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for
years, steep price declines.
MoreProfits at center of biosimilars debate
March 18, 2013
J.K. WallHouse Bill 1315, which is scheduled for a Senate floor hearing on Monday, would require pharmacists to check with a patient’s
physician before automatically substituting a generic version of a biotech drug for a brand-name version.
MoreQ&A
March 11, 2013
J.K. WallMike Sherman, the chief financial officer at West Lafayette-based Endocyte Inc., talked about how the drug
firm’s funding partnership with New Jersey-based Merck & Co. Inc. has helped accelerate development of the company’s
pipeline, which is branching out into drugs to treat cancers of the lung, prostate and breast.
MoreEndocyte stock sinks due to possible drug-filing delay
February 26, 2013
J.K. WallEndocyte Inc. saw its shares fall nearly 7 percent Tuesday morning after the drug development firm announced that its application
for U.S. approval of a cancer drug could be delayed another 10 months.
MoreLilly halts late-stage testing of rheumatoid arthritis drug
February 7, 2013
Bloomberg NewsEli Lilly said it is halting testing of experimental drug tabalumab because the studies show the medicine is not effective.
The company said it expects to take a $50 million charge in the first quarter related to the research expenses from the drug.
MoreLilly aims to submit five new drugs for approval
February 4, 2013
J.K. WallWith Eli Lilly and Co. set to see patents expire on its best-selling drug at year’s end, it is in the company’s
interest to say its pipeline is about to produce new drugs. But the Indianapolis drugmaker may be in a position to submit
five new drugs for regulatory approval this year.
MoreOnce-thriving drug lab in turnaround mode
January 26, 2013
J.K. WallTwo years ago, executives at AIT Laboratories “took their eye off the ball,” and watched the company’s business
plummet 29 percent in value. Now, after two years of turmoil, the drug-testing lab says it’s poised to return to the
double-digit rates of growth that made it a local star.
MoreLilly finds solace in new Alzheimer's study
December 17, 2012
J.K. WallEli Lilly and Co. suffered a delay in its effort to bring an Alzheimer’s drug to market this month, but it also published
new research that the pharmaceutical company thinks confirms it is on the right track.
MoreLilly discontinues late-stage trial in rheumatoid arthritis
December 13, 2012
Bloomberg NewsEli Lilly and Co. said it discontinued a last-stage trial of experimental rheumatoid arthritis drug tabalumab for lack of
efficacy. Lilly is still evaluating the drug in the two other late-stage studies.
MoreLilly chief says China too slow in approving new drugs
November 28, 2012
Bloomberg NewsChina takes eight years longer on average to approve drugs than other major countries, and U.S. drugmakers are looking at
ways to help speed things up, Eli Lilly and Co. CEO John Lechleiter said.
MoreDrugmakers collaborate to facilitate drug tests
November 15, 2012
Associated PressEli Lilly and Co. and two other major drugmakers say they are collaborating in a global project aimed at getting patient tests
of experimental drugs up and running more quickly and efficiently.
MoreLife sciences finance pro heading to startup
November 10, 2012
Chris O'MalleyIf a biotech startup were akin to a rock band, Kristin Sherman might be the keyboardist. She’s not front-and-center
on the stage, but the ballad wouldn’t be as dynamic without her pounding the chords.
MoreLilly continues string of positive trials
October 22, 2012
J.K. WallEli Lilly and Co. is continuing a string of positive yet incomplete clinical trial results, giving it a boost among investors.
MoreAlzheimer’s prevention seen promising as drug cures fail
October 19, 2012
Bloomberg NewsResearchers are set to test drugs by Eli Lilly and other companies that may prevent Alzheimer’s disease after efforts
to find a cure have been unsuccessful.
MoreLilly, Roche drugs chosen for Alzheimer’s prevention trial
October 10, 2012
Bloomberg NewsEli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s
trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.
MoreLilly shares rise on Alzheimer's study results
October 8, 2012
J.K. WallEli Lilly and Co.’s Alzheimer’s drug slowed cognitive decline 34 percent in patients with mild forms of the disease,
according to an analysis of Lilly’s clinical trial data released Monday. Lilly’s share price jumped more than
5 percent on the news.
MoreLilly counting on diabetes products to challenge larger rivals
October 8, 2012
Bloomberg NewsEli Lilly and Co. is betting on a “broad” range of diabetes products including pills, insulins and a once-a-week
treatment to take on bigger competitors, said Enrique Conterno, president of Lilly Diabetes.
MoreTen drugmakers team up to improve testing process
September 19, 2012
Associated PressPharmaceutical industry heavyweights, including Eli Lilly and Co., are teaming up to improve the way experimental drugs are
tested so they can get approved, and reach patients, faster.
MoreTwo more clinical trials go against Lilly
September 4, 2012
J.K. WallIn the midst of Eli Lilly and Co.’s surprisingly positive news about its experimental Alzheimer’s drug, the company
suffered two other setbacks with former stars of its pipeline.
MoreLilly stops testing of experimental schizophrenia drug
August 29, 2012
Bloomberg NewsEli Lilly and Co. halted testing on an experimental treatment for schizophrenia after the company determined the drug was
unlikely to show a benefit in patients.
MoreLilly's Alzheimer's finding triggers investor hope, doctor caution
August 27, 2012
Bloomberg NewsWhile investors supported the sliver of promise offered when Eli Lilly and Co. said its Alzheimer’s drug may slow progression
early in the disease, doctors weren’t as impressed, saying it could take years to find out for sure.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Who makes Tater Tots? They would be a good sponsor, because $3 Million for the alleged "Greatest Spectacle In Racing" is taters. Tiny, tiny taters. But at least they are making up something of the losses accumulated over the years in this dying sport. Buttock in seat is certainly not doing it, nor eyeball on TV, as evidenced by the lack of both.
We loved lakehouse and think the Arbor Village would be a great location. It is less than 2 miles from over 1000 rooftops in the 225,000 to over 1 million range. Many people could use the great fishers trail system to bike or walk there. Just an idea Scotty -- but maybe something closer to 3 Wiseman would good. The only microbrew in area is Ram (boring)
True, it's an ESPN production, but ESPN is just another name for ABC Sports, or what used to be ABC Sports since ABC Sports no longer exists as a name. ESPN=ABC Sports= ESPN. ESPN is, according to Forbes "the world's most valuable media property" worth $40 billion. Despite that, they fired 400 people this week.
The Prestige was a great flick.
Larry - even though the race is on ABC, ESPN does all of the work, so that is why ESPN is mentioned. Most sports on ABC are called something like "ESPN on ABC."